These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8370632)

  • 21. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine.
    Yacobi A; Zlotnick S; Colaizzi JL; Moros D; Masson E; Abolfathi Z; LeBel M; Mehta R; Golander Y; Levitt B
    Clin Pharmacol Ther; 1999 Apr; 65(4):389-94. PubMed ID: 10223775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioimmunological analysis of cyproterone acetate in human serum. Comparison with a gas chromatographic/mass spectrometric method and influence of each method on the outcome of a bioequivalence trial.
    Baumann A; Kulmann H; Gorkov V; Mahler M; Kuhnz W
    Arzneimittelforschung; 1996 Apr; 46(4):412-8. PubMed ID: 8740090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies.
    Mahmood I; Mahayni H
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):275-81. PubMed ID: 10395118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limitations of Levothyroxine Bioequivalence Evaluation: Analysis of An Attempted Study.
    Mayor GH; Orlando T; Kurtz NM
    Am J Ther; 1995 Jun; 2(6):417-432. PubMed ID: 11850687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies.
    Hauschke D; Steinijans WV; Diletti E; Schall R; Luus HG; Elze M; Blume H
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):376-8. PubMed ID: 7952801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comment on so-called individual criteria of bioequivalence.
    Wellek S
    J Biopharm Stat; 1997 Mar; 7(1):17-21. PubMed ID: 9056583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size considerations for assessing individual bioequivalence based on the method of tolerance intervals.
    Esinhart JD; Chinchilli VM
    Int J Clin Pharmacol Ther; 1994 Jan; 32(1):26-32. PubMed ID: 8199749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of human serum insulin concentrations in clinical pharmacokinetic or bioequivalence studies: what defines the "best method"?
    Cassidy JP; Luzio SD; Marino MT; Baughman RA
    Clin Chem Lab Med; 2012 Jan; 50(4):663-6. PubMed ID: 22505557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Analysis of bioequivalence trials. From analysis to statistic trials].
    Houin G
    Therapie; 1993; 48(4):289-95. PubMed ID: 8128417
    [No Abstract]   [Full Text] [Related]  

  • 31. Interlaboratory comparison of blood lead determinations.
    Maher CC; Roettgers DM; Conlon HJ
    Am Ind Hyg Assoc J; 1979 Mar; 40(3):230-7. PubMed ID: 495462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of in vivo bioequivalence.
    Jackson AJ
    Pharm Res; 2002 Mar; 19(3):227-8. PubMed ID: 11934226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The practical value of determination of plasma levels of drugs].
    Valiente R; Flórez J
    Rev Med Univ Navarra; 1988; 32(1):21-8. PubMed ID: 3154928
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug Product Selection--Part 2: Scientific basis of bioavailability and bioequivalence testing.
    Meyer MC
    Am Pharm; 1991 Aug; NS31(8):47-52. PubMed ID: 1927900
    [No Abstract]   [Full Text] [Related]  

  • 35. An application of the Mantel-Haenszel statistic in process validation.
    Fairweather WR
    J Biopharm Stat; 2005; 15(2):253-64. PubMed ID: 15796293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commentary on individual bioequivalence by M.-L. Chen.
    Hauck WW; Anderson S
    J Biopharm Stat; 1997 Mar; 7(1):13-6. PubMed ID: 9056582
    [No Abstract]   [Full Text] [Related]  

  • 37. Practical application of statistical models aimed at assessing bioequivalence through network meta-analysis.
    Messori A
    Eur J Clin Pharmacol; 2014 Dec; 70(12):1527-8. PubMed ID: 25228252
    [No Abstract]   [Full Text] [Related]  

  • 38. Is the effect of hemolysis on plasma ammonia measurement overrated?
    El-Khoury JM; Bunch DR; Wang S
    Arch Pathol Lab Med; 2012 May; 136(5):471-2. PubMed ID: 22540295
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug absorption rate: a critical component of bioequivalence assessment in psychopharmacology.
    Greenblatt DJ; Shader RI
    J Clin Pharmacol; 1987 Feb; 27(2):85-6. PubMed ID: 3680569
    [No Abstract]   [Full Text] [Related]  

  • 40. Quantifying oxidant-scavenging ability of blood.
    Ginsburg I; Kohen R; Koren E
    N Engl J Med; 2011 Mar; 364(9):883-5. PubMed ID: 21366487
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.